Insights

Why Pfizer and BioNTech stocks popped Wednesday

The healthcare leaders became the first to receive emergency authorization for their coronavirus vaccine.
The post Why Pfizer and BioNTech stocks popped Wednesday appeared first on Motley Fool Australia. –

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

woman waering face mask holding vial of covid-19 vaccine

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

What happened

Shares of Pfizer Inc (NYSE: PFE) and BioNTech (NASDAQ: BNTX) climbed on Wednesday after the pharmaceutical titan and biotech announced a major development in the battle against COVID-19. As of 2:40 p.m. EST, Pfizer’s and BioNTech’s stocks were up 3% and 5.6%, respectively.

So what

A phase 3 trial showed Pfizer’s and BioNTech’s vaccine candidate BNT162b2 to be as much as 95% effective at preventing COVID-19. And importantly, BNT162b2 was generally well tolerated with no serious safety concerns observed among the study’s participants to date. This promising data prompted the U.K. government to grant emergency authorization for the COVID-19 vaccine. 

“Today’s Emergency Use Authorization in the U.K. marks a historic moment in the fight against COVID-19,” Pfizer CEO Albert Bourla said in a press release. “This authorization is a goal we have been working toward since we first declared that science will win.”

Pfizer and BioNTech have agreed to supply the U.K. with 40 million doses of the vaccine. The healthcare companies will begin delivering the vaccine immediately, with the first doses expected to arrive in the coming days. 

Now what 

The U.K.’s decision is a major step forward in the war against the dangerous disease. COVID-19 case counts remain at alarmingly high levels in many areas of the world. A safe and effective vaccine could help to slow the spread of the disease and eventually help to bring about an end to the pandemic.

Pfizer and BioNTech stand ready to deliver their vaccine to more countries in the weeks ahead. They have requested emergency authorization from health regulators in the U.S. and Europe. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are expected to announce their decisions later this month.

“As we anticipate further authorizations and approvals, we are focused on moving with the same level of urgency to safely supply a high-quality vaccine around the world,” Bourla said. “With thousands of people becoming infected, every day matters in the collective race to end this devastating pandemic.”

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why Pfizer and BioNTech stocks popped Wednesday appeared first on Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!